A study supported by a grant from the National Institutes of Health and completed by researchers at the University of Vermont Cancer Center suggests that platelet FcγRIIa may help identify cancer patients at greater risk of thromboembolic events and death. Titled “Platelet FcγRIIa: A Novel Biomarker of Risk for Thromboembolism and Death in Cancer,” the study was published in the Journal of Thrombosis and Thrombolysis. Study co-author Chris E. Holmes, M.D., Ph.D., Department of Medicine, Division of Hematology and Oncology, University of Vermont Cancer Center, said, “While additional studies are needed, these results indicate that platelet FcγRIIa could emerge as a valuable biomarker for identifying cancer patients who may face a greater risk of thrombosis and poor outcomes.”
Read full story at the Standard-Journal
This story was also covered in the Batesville (Ark.) Guard.